The presence of elevated calculated panel reactive antibody (cPRA) and anti-HLA donor
specific antibodies (DSA) are high risk factors for acute antibody-mediated rejection (AAMR)
in intestinal transplantation that may lead to graft loss. Eculizumab has been used for the
treatment of AAMR in kidney transplantation of sensitized patients that do not respond to
other treatment. Here, we report a case where eculizumab was used to treat AAMR in a
desensitization-resistant intestinal re-transplant patient. A male patient lost his intestinal graft …